New pill could help ITP patients when first treatment fails
NCT ID NCT07007962
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tests an oral drug called rilzabrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed first-line treatment. The goal is to see if the drug can safely raise platelet counts to safer levels. About 60 people will take the pill and be monitored for up to 28 weeks, with an optional extension.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Community Cancer Trials of Utah-Investigational Site Number: 8400002
RECRUITINGOgden, Utah, 84405, United States
-
Investigational Site Number : 0400001
RECRUITINGVienna, 1140, Austria
-
Investigational Site Number : 2500001
RECRUITINGDijon, 21079, France
-
Investigational Site Number : 2500002
RECRUITINGPessac, 33604, France
-
Investigational Site Number : 2500004
RECRUITINGToulouse, 31059, France
-
Investigational Site Number : 3480002
RECRUITINGKaposvár, 7400, Hungary
-
Investigational Site Number : 3800003
RECRUITINGVicenza, 36100, Italy
-
Investigational Site Number : 3800006
RECRUITINGNaples, 80131, Italy
-
Investigational Site Number : 3800007
RECRUITINGTorino, 10126, Italy
-
Investigational Site Number : 6160002
RECRUITINGGdansk, 80-219, Poland
-
Investigational Site Number : 6160003
RECRUITINGSkorzewo, 60-185, Poland
-
Investigational Site Number : 6160004
RECRUITINGSłupsk, 76-200, Poland
-
Investigational Site Number : 7240001
RECRUITINGBarcelona, 8003, Spain
-
Investigational Site Number : 7240002
RECRUITINGBurgos, 9006, Spain
-
Investigational Site Number : 7240004
RECRUITINGSeville, 41013, Spain
-
Investigational Site Number : 7240005
RECRUITINGMurcia, 30008, Spain
-
Investigational Site Number : 7240007
RECRUITINGMadrid, 28007, Spain
-
Investigational Site Number : 7240008
RECRUITINGMadrid, 28046, Spain
-
Investigational Site Number: 2500003
RECRUITINGCréteil, 94000, France
-
Mayo Clinic_Investigational Site Number: 8400009
RECRUITINGRochester, Minnesota, 55905, United States
-
Montefiore Medical Center-Investigational Site Number: 8400012
RECRUITINGThe Bronx, New York, 10467, United States
-
New York Oncology Hematology-Investigational Site Number: 8400010
RECRUITINGAlbany, New York, 12208, United States
-
Tulane University Health Sciences Center - Tulane Avenue-Investigational Site Number: 8400011
RECRUITINGNew Orleans, Louisiana, 70112, United States
-
University of Michigan Health - Michigan Medicine - University Hospital-Investigational Site Number: 8400001
RECRUITINGAnn Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.